Eton Pharmaceuticals Inc · Q1 2026 earnings

Briefing

Eton Pharmaceuticals Inc reported net income of $1.6 million on revenue of $24.3 million for Q1 2026.

Eton Pharmaceuticals achieved strong revenue growth in Q1 2026 with total net revenues of $24.3 million, up 40% year-over-year, driven by increased product sales of rare disease treatments including INCRELEX, GALZIN, and new launches. The company recorded net income of $1.6 million versus a $1.6 million loss in the prior year period, reflecting improved gross margins and disciplined operating expense management. Cash and cash equivalents stood at $19.7 million with total assets of $97.7 million at quarter end.

• Total net revenues rose 40% to $24.3 million, led by product sales and royalties of $24.3 million
• Achieved net income of $1.6 million and operating income of $2.4 million compared to prior year loss
• Gross profit increased to $14.7 million with gross margin expansion from higher-margin product mix
• Adjusted EBITDA reached $5.7 million; cash position remained solid at $19.7 million after licensing acquisitions

Headline financials

Revenue & EPS history

Company continues commercial execution and portfolio expansion for rare disease products with no quantitative guidance provided.